Billy Michael Chelliah Jebaraj
- Genetics top 5%
- Chronic Lymphocytic Leukemia Research 15
-
- Lymphoma Diagnosis and Treatment 3
-
- Acute Myeloid Leukemia Research 3
- Chronic Myeloid Leukemia Treatments 3
-
- Telomeres, Telomerase, and Senescence 5
-
- Acute Lymphoblastic Leukemia research 3
-
- PI3K/AKT/mTOR signaling in cancer 3
-
- Advanced Breast Cancer Therapies 2
- Co-authors
- Stephan StilgenbauerAnnika ScheffoldHartmut DöhnerMartina SeiffertThorsten ZenzPhilipp M. RoessnerDirk KienleAndreas Bühler
- Partner nations
- GermanyUnited StatesSwitzerland
In The Last Decade
Billy Michael Chelliah Jebaraj
15 papers receiving 294 citations
Peers
Comparison fields: 5 of 45
- Genetics 173
- Pathology and Forensic Medicine 99
- Aging 9
- Hematology 55
- Immunology 75
Countries citing papers authored by Billy Michael Chelliah Jebaraj
This map shows the geographic impact of Billy Michael Chelliah Jebaraj's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Billy Michael Chelliah Jebaraj with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Billy Michael Chelliah Jebaraj more than expected).
Fields of papers citing papers by Billy Michael Chelliah Jebaraj
This network shows the impact of papers produced by Billy Michael Chelliah Jebaraj. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Billy Michael Chelliah Jebaraj. The network helps show where Billy Michael Chelliah Jebaraj may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Billy Michael Chelliah Jebaraj, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2026 | 0 | |
| 2 | 2025 | 1 | |
| 3 | 2024 | 0 | |
| 4 | 2021 | 16 | |
| 5 | 2021 | 2 | |
| 6 | 2021 | 23 | |
| 7 | 2019 | 44 | |
| 8 | 2019 | 1 | |
| 9 | 2018 | 49 | |
| 10 | 2018 | 26 | |
| 11 | 2018 | 1 | |
| 12 | 2017 | 0 | |
| 13 | 2017 | 13 | |
| 14 | 2016 | 41 | |
| 15 | 2016 | 20 | |
| 16 | 2016 | 6 | |
| 17 | 2013 | 1 | |
| 18 | 2012 | 41 | |
| 19 | 2012 | 15 |
About Billy Michael Chelliah Jebaraj
Billy Michael Chelliah Jebaraj is a scholar working on Genetics, Hematology and Physiology, having authored 19 papers that have together received 300 indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (15 papers), Telomeres, Telomerase, and Senescence (5 papers), Acute Myeloid Leukemia Research (3 papers), Acute Lymphoblastic Leukemia research (3 papers), Lymphoma Diagnosis and Treatment (3 papers), Chronic Myeloid Leukemia Treatments (3 papers), PI3K/AKT/mTOR signaling in cancer (3 papers) and Advanced Breast Cancer Therapies (2 papers). The work is most often cited by research in Genetics (173 citations), Pathology and Forensic Medicine (99 citations) and Aging (9 citations). Billy Michael Chelliah Jebaraj has collaborated with scholars based in Germany, United States and Switzerland. Frequent co-authors include Stephan Stilgenbauer, Annika Scheffold, Hartmut Döhner, Martina Seiffert, Thorsten Zenz, Philipp M. Roessner, Dirk Kienle, Andreas Bühler, Eugen Tausch and Dirk Winkler. Their work appears in journals such as Blood, Leukemia and Frontiers in Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.